Zacks Investment Research upgraded shares of EDAP TMS SA (NASDAQ:EDAP) from a hold rating to a buy rating in a research report report published on Tuesday morning. Zacks Investment Research currently has $3.25 price target on the stock.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other analysts have also recently commented on the company. HC Wainwright reiterated a buy rating on shares of EDAP TMS SA in a report on Tuesday, August 30th. TheStreet upgraded EDAP TMS SA from a sell rating to a hold rating in a report on Tuesday, September 27th.

EDAP TMS SA (NASDAQ:EDAP) opened at 2.81 on Tuesday. EDAP TMS SA has a 52 week low of $2.43 and a 52 week high of $6.57. The stock has a 50 day moving average of $2.89 and a 200 day moving average of $3.24. The company has a market cap of $80.72 million, a price-to-earnings ratio of 17.13 and a beta of 1.12.

EDAP TMS SA (NASDAQ:EDAP) last announced its earnings results on Thursday, August 25th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.12. EDAP TMS SA had a return on equity of 58.61% and a net margin of 11.53%. Equities research analysts predict that EDAP TMS SA will post $0.16 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in EDAP TMS SA stock. Perkins Capital Management Inc. purchased a new position in EDAP TMS SA (NASDAQ:EDAP) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 118,000 shares of the company’s stock, valued at approximately $391,000. Perkins Capital Management Inc. owned 0.46% of EDAP TMS SA as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.72% of the company’s stock.


EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

5 Day Chart for NASDAQ:EDAP

Get a free copy of the Zacks research report on EDAP TMS SA (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for EDAP TMS SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS SA and related companies with's FREE daily email newsletter.